NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/09/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization8.45 mln
Float0.56 mln
Earnings Date11/13/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
0
/ 100
Severely lagging
Debt / Equity
0.01
Debt-free
ROE
-88.79
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
CDT Equity Inc. is a clinical-stage pharmaceutical company focused on developing treatments for autoimmune conditions and unexplained male infertility. Its two lead drug candidates, AZD1656 and AZD5904, have each completed Phase I clinical trials across several indications, including kidney transplant rejection, thyroid disease, eye inflammation, and premature labor. The company works with Agility Life Sciences, a specialist drug development partner, to create new oral solid-dose formulations. Founded in 2019 and headquartered in Naples, Florida, the company was previously called Conduit Pharmaceuticals Inc. before renaming itself in August 2025.
